Press release
Incyte Announces Positive Topline Results from Phase 3 Trial Evaluating Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
Phase 3 TruE-AD3 Study met its primary endpoint WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announced positive topline results from its
About this update from Incyte Corporation
[{"type":"text","content":"\nPhase 3 TruE-AD3 Study met its primary endpoint\n\n\n WILMINGTON, Del.--(BUSINESS WIRE)--\nIncyte (Nasdaq:INCY) today announced positive topline results from its randomized, vehicle-controlled, pivotal Phase 3 TRuE-AD3 study evaluating the safety and efficacy of ruxolitinib cream (Opzelura®) in children (age ≥2 to","length":501,"tagName":"div"}]